Alkeus Announces $150 Million Series B Financing, Supporting Rapid Registration Path For Gildeuretinol (Alk-001) In The Treatment Of Stargardt Disease
Amount Raised
$150 Million
Round Type
Series B
CambridgeBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaDescription
Alkeus Pharmaceuticals announced today that it has raised a $150 million Series B financing to support the registration and launch of gildeuretinol (ALK-001), a potential disease-modifying, precision medicine for the treatment of Stargardt disease, a leading genetic cause of blindness in children and young adults. The financing was led by Bain Capital Life Sciences, with additional participation by TCGX, Wellington Management and Sofinnova Investments. Alkeus also announced today that Joshua Boger, Ph.D., a biotech industry pioneer and the founder of Vertex Pharmaceuticals, has joined Alkeus as Executive Chairman.
Quick answer
Alkeus Pharmaceuticals raised $150 Million in a Series B round, dated June 5, 2023. Alkeus Pharmaceuticals is based in Cambridge, Massachusetts, United States.
- How much did Alkeus Pharmaceuticals raise?
- Alkeus Pharmaceuticals raised $150 Million in a Series B round on June 5, 2023.
- What does Alkeus Pharmaceuticals do?
- Alkeus Pharmaceuticals is a biopharmaceutical company headquartered in Cambridge, Massachusetts.
- Where is Alkeus Pharmaceuticals based and how big is it?
- Alkeus Pharmaceuticals is based in Cambridge, Massachusetts, United States.
- Who are the decision-makers at Alkeus Pharmaceuticals?
- Fundz holds 1 contact at Alkeus Pharmaceuticals. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Pharmaceutical around the same time
Companies in the same sectors as Alkeus Pharmaceuticals that raised within 45 days of this round, from Fundz verified event records.
- Foresee Pharmaceuticals raised $42M (Funding Round) on June 27, 2023.
- Decoy Therapeutics Inc. raised $6M on May 11, 2023.
- Mezzion Pharma raised $40M (Funding Round) on April 25, 2023.
- Gossamer Bio raised $212M (Post-IPO Equity) on July 20, 2023.
- Renibus Therapeutics raised $47M (Funding Round) on July 18, 2023.
- DiaMedica Therapeutics raised $38M on June 23, 2023.
Who to call at Alkeus Pharmaceuticals, and when
A new round usually means Alkeus Pharmaceuticals is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Alkeus Pharmaceuticals raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Alkeus Pharmaceuticals, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Alkeus Pharmaceuticals. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Alkeus Pharmaceuticals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansAlkeus Pharmaceuticals raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.